甲状腺乳头状癌中BRAF V600E突变及其与甲状腺超声表现的关系

    Correlation between BRAF V600E mutation in papillary thyroid carcinoma and the sonographic findings

    • 摘要: 目的:探讨甲状腺乳头状癌(papillary thyroid carcinoma,PTC)中BRAF V600E突变及其与甲状腺超声表现的关系。方法:采用PCR反应扩增及DNA直接测序法检测34例PTC患者手术切除的新鲜甲状腺组织及其癌旁组织的BRAF V600E突变情况,比较PTC发生和未发生BRAF V600E突变患者的甲状腺超声检查影像。结果:34例PTC癌组织标本中有18例发生BRAF V600E突变,16例未发生突变;34例PTC癌旁组织标本均未检测到BRAF V600E突变。PTC BRAF V600E突变患者与未发生突变患者甲状腺超声检查的癌块大小、边界是否清楚及有无钙化差异均无统计学意义(P>0.05)。结论:PTC中BRAFV600E突变率较高;BRAF V600E突变与甲状腺超声表现无明显关系。甲状腺超声表现不能预测PTC中BRAF V600E突变的存在。

       

      Abstract: Objective: To observe the relationship between BRAF V600E mutation in papillary thyroid carcinoma (PTC) and the sonographic findings.Methods: The study included 34 fresh PTC tissue samples and the neighboring tissues from the patients surgically confirmed PTC.The BRAF V600E mutation of all the cases was determined by allelespecific polymerase chain reaction and direct DNA sequencing.The ultrasound findings were compared between the nodules with and without mutation.Results: Of the 34 carcinoma samples,BRAF V600E mutation was observed in 18 cases and no BRAF V600E mutation in 16 cases.Of all the 34 neighboring samples,BRAF V600E mutation was observed in no one.The sonographic findings showed that patients with BRAF V600E mutation had no significant difference with those without BRAF V600E mutation in the tumor size,margin or calcification (P>0.05).Conclusions: BRAF V600E mutation is frequently observed in patients with PTC,and it has no significant connection with the sonographic findings of the nodules.Sonographic findings can't predict BRAF V600E mutation in the PTC.

       

    /

    返回文章
    返回